Lurbinectedin Deemed “Valuable” Treatment Option for Relapsed Ewing Sarcoma
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
Sarcoma News
SARCOMA CANCER ADVISOR
Sarcoma News
Intensification Does Not Improve Survival in Metastatic Ewing Sarcoma
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
Molecular Profiling Can Guide Treatment After Recurrence in Young Cancer Patients
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Eponyms in Oncology: Li-Fraumeni Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Irinotecan-Temozolomide “Effective and Safe” for Relapsed Ewing Sarcoma
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.
Cesarean Birth May Be Associated With Increased Childhood Cancer Risk
Cesarean was associated with increased risk of any cancer, hematopoietic cancers, and solid tumors.
Osteosarcoma Incidence Highest in Black Patients
Black individuals had the highest incidence of osteosarcoma, but the worst survival was seen in American Indian/Alaska Native individuals.
Eponyms in Oncology: Kaposi Sarcoma
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Kaposi sarcoma.
SLN Biopsy Does Not Compromise Outcomes in Uterine Carcinosarcoma
Systematic lymph node dissection did not provide a survival benefit over sentinel lymph node biopsy alone in patients with uterine carcinosarcoma.
Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Bone Cancer Survivors Are at Increased Risk of Neurocognitive Difficulties
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
Hyperprogression After PD-1 Blockade Observed in Sarcoma Patients
The rate of hyperprogressive disease was 11%.
Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
The approval of Fyarro was based on data from the phase 2 AMPECT study.
Long-Term Safety Data Support Benefit-Risk Profile of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
NBTXR3 plus radiotherapy did not negatively affect quality of life or long-term morbidity in locally advanced soft tissue sarcoma.
Lack of Radiosensitivity Associated With Poor Outcomes in Myxoid Liposarcomas
Researchers found that lack of radiosensitivity was associated with poor outcomes in patients with myxoid liposarcomas.
Radiotherapy May Improve Outcomes in Extremity Soft Tissue Sarcoma
Neoadjuvant and adjuvant radiotherapy were associated with a reduced risk of local recurrence.
Immune Checkpoint Inhibitors May Offer Benefit in Recurrent Chordoma
Most patients included in the retrospective analysis received ICI treatment as their first line of therapy (59%).
Regimen May Be Beneficial as Palliative Care for Children, Young Adults With Solid Tumors
Stable disease was observed in 51.3% of patients.
Lower Household Income May Increase Risk of Amputation in Extremity Bone Sarcoma
Amputation was significantly more likely in patients with household incomes below $75,000 per year.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...